Investors found something to like about the company's recent round of clinical trials for a key pipeline medication.Although the latest news from the laboratory was mixed for pharmaceutical company Sanofi (SNY 2.26%) on Tuesday, investors gave the company the benefit of the doubt. They bid the share price up by more than 2% on the day, making it a mirror image of the 2%-plus decline of the S&P 500 index. 1 out of 3 trials was a successSanofi published readouts of three phase 3 trials of its tolebrutinib mul ...